Received October 8, 2010 . Accepted March 10, 2011 . Available online March 25, 2011 . Published June 13, 2011. Colon cancer, which is the second most prevalent type of cancer in the world, is an important public health problem that is related to life style, especially eating habits (1) .
Bioactive compounds present in foods, such as isoprenic derivatives found in fruits and vegetables, are potential chemopreventive agents against cancer (2, 3) . Promising dietary isoprenoids are β-ionone (βI), a cyclic isoprenoid, the product of β-carotene degradation, which is present mainly in grapes and wine aromatizers, and geraniol (GO), an acyclic monoterpene, which is an important constituent of the essential oils of ginger, lemon, lime, orange, and nutmeg ( Figure 1 ). Both compounds are of interest to the detergent, perfume and food industries because of their floral aromatics and antifungal and antioxidant properties (4, 5) .
Several in vitro studies have shown that βI and GO suppressed cell proliferation and/or stimulated apoptosis in diverse tumor lines, including Caco-2 human colon adenocarcinoma cells (6, 7) . In the few available in vivo studies, both compounds exerted chemopreventive activity against hepatocarcinogenesis in rats ( [8] [9] [10] . GO inhibited the growth of mammary and pancreatic neoplasms in rats and hamsters, respectively (11, 12) , and proved to be an effective adjuvant in the treatment with 5-fluorouracil of human colorectal cancer cells transplanted in Swiss nu/ nu mice (13) . βI also reduced the incidence of mammary neoplasms in rats (3, 11) and, more recently, it was shown to inhibit the number and size of preneoplastic lesions (PNLs) in the colon when administered in the diet to F344 rats (14) . Similarly, other isoprenoids such as perillyl alcohol (15) , squalene (16) , geranylgeraniol, farnesol, and lanosterol (17, 18 ) also showed chemopreventive activity in a colon carcinogenesis model induced by azoxymethane.
One mechanism of action proposed for the chemopreventive action of isoprenoids is related to the suppression of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity (6, 19) , which is frequently elevated and deregulated in PNLs and neoplastic tissues (2) . The inhibition of HMG-CoA reductase and intermediates of the mevalonate pathway is related to the suppression of cell proliferation and induction of apoptosis (2, 6, 20) . The Bcl-2 family of proteins has also been implicated in cell death induction by dietary isoprenoids (21, 22) and reports of changes in expression of Bcl-2 in colon carcinogenesis confirm that this protein may be involved in the primary mechanism of homeostasis in the colonic epithelium (23) . Additive and synergistic inhibitory effects have been described after treatment of neoplastic cell lines with a combination of cyclic and acyclic isoprenoids (24, 25) .
Because βI and GO had chemopreventive activity in different models (8) (9) (10) 12) , including colon carcinogenesis in the case of βI (14), we hypothesized that the combination of βI and GO could result in synergistic chemopreventive activity. Therefore, we investigated the chemopreventive potential of the combination of βI and GO during the initiation and postinitiation phases of a rat colon carcinogenesis model induced by dimethylhydrazine (DMH). The parameters evaluated included aberrant crypt foci (ACF), which are considered to be PNLs and are widely used as a colon carcinogenesis biomarker (26) , plasma concentrations of total cholesterol, DNA damage (Comet test), expression of proliferating cell nuclear antigen (PCNA) and Bcl-2 proteins, and concentrations of βI and GO in colonic samples.
Material and Methods

Chemicals
βI (4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3(E)-buten-2-one; 95%), GO (trans-3,7-dimethyl-2,6-octadien-1-ol; 98%) and DMH (>99%) were purchased from Sigma (USA). The commercial diet was purchased from Purina (Brazil), and the corn oil (CO) was from Mazola ® (Brazil). The polyclonal anti-Bcl-2 rabbit antibody was purchased from Santa Cruz Biotechnology (USA). The monoclonal anti-PCNA, secondary biotinylated antibody and streptavidin-biotin-peroxidase complex (StrepABComplex/HRP Duet, Mouse/Rabbit) were purchased from Dako (Denmark). The nitrocellulose membrane (Hybond TM-C extra), ECL chemiluminescence kit and ECL-advanced chemiluminescence kit were purchased from Amersham Biosciences (USA). The total plasma cholesterol kit was purchased from BioSystems (Spain). NE-PER, T-PER and BCA protein assay kits were purchased from Pierce (USA). All other chemicals were of the highest available quality.
Animals and experimental protocol
Three-week-old male Wistar rats from the colony of the Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, were used. The animals, initially weighing 40-50 g, were maintained in cages in groups of 4 at a constant temperature (22°C) and on a 12-h light-dark cycle and received water and commercial diet ad libitum. At the end of a 7-day acclimatization period, with the exception of 6 rats not subjected to any experimental procedure (Normal (N) group), 48 animals (12 animals per group) were treated daily for 9 consecutive weeks with: βI (βI group; 16 mg/100 g body weight), GO (GO group; 25 mg/100 g body weight) or βI combined with GO (βI+GO group; βI (16 mg/100 g body weight) plus GO (25 mg/100 g body weight) dissolved in CO (0.25 mL/100 g body weight). Animals receiving only CO (0.25 mL/100 g body weight) were used as controls (CO group). On the 3rd and 4th weeks of treatment, the CO, βI, GO and βI+GO groups received ip injections of DMH (40 mg/kg body weight) twice a week (27) . After 9 weeks of treatment, the animals were euthanized by exsanguination under anesthesia (Figure 2 ). The study was approved by the Ethics Committee for Animal Research of the Faculty of Pharmaceutical Sciences, University of São Paulo (Protocol #75). At autopsy, the colons were opened and divided longitudinally into 2 hemicolons; one hemicolonic segment was fixed flat in 70% ethanol and divided into 2 regions: proximal and distal. The other hemicolonic segment had its mucosa scraped and was stored at -80°C (28, 29) for later determination of DNA damage (Comet assay), PCNA and Bcl-2 expression and βI and GO concentration.
Quantification of ACF in the colonic mucosa
ACF were scored as previously described (26) . Colonic segments were stained for 10 min with 0.02% methylene blue in phosphate-buffered saline (PBS; 2.7 mM KCl, 8.1 mM Na 2 PO 4 , 1.5 mM KH 2 PO 4 , 0.14 M NaCl, pH 7.6) (27) . Methylene blue-stained ACF, analyzed from the mucosal surface by transmitted light at 40X magnification, appeared as collections of elevated crypts with increased staining and expanded pericryptal spaces (26) (27) (28) . The ACF location (distal or proximal colon) and the multiplicity of each focus (number of crypts/ACF) were recorded.
Total plasma cholesterol concentration
Blood was collected by puncture of the abdominal aorta at the time of euthanasia. Immediately after collection, it was placed in centrifuge tubes containing 5 mg EDTA and centrifuged at 3500 g, 4°C for 10 min. Total plasma cholesterol concentration was determined using an enzymatic-spectrophotometric technique (10) . Analysis was performed at 500 nm with a Hitachi U 110 spectrophotometer (Japan).
Colonic DNA strand breakage (single-cell gel electrophoresis -Comet test)
Colonic DNA strand breakage was evaluated in colonic mucosa samples stored at -80°C using the Comet assay as described previously (9) . The tissues were smoothly homogenized in PBS under refrigeration, and filtered. The isolated cells were then immobilized in a low-melting agarose matrix on a glass slide. The slides were then transferred to the lysis solution (2.5 M NaCl, 100 mM EDTA, 10 mM Trizma Base, 10% DMSO, 1% N-laurylsarcosine, pH adjusted to 10, and addition of 1% Triton X-100). After 1 h, the slides were washed three times for 20 min with water and placed in a horizontal electrophoresis unit containing the running buffer (300 mM NaOH and 1 mM EDTA, pH >13) where they remained immersed for 20 min at 5°C. Electrophoresis was performed for 20 min at 0.9 V/cm at 5°C. The resulting comets were neutralized with 0.4 M Tris three times for 5 min and stained with silver nitrate. Normal rat colonic tissues, treated or not with hydrogen peroxide (HP; 10% final concentration, 5 min at room temperature and sonication) were used as positive and negative controls, respectively.
The length of the comets was evaluated using a previously described image analysis system (8, 9) . One hundred nucleoids per animal were randomly analyzed (50 images per slide) and encoded slides were scored blindly. The viability of the colonic mucosa cells was indirectly determined by analyzing the comet images after silver staining.
Apoptosis analysis
Apoptosis was identified in hematoxylin-eosin (HE)-stained proximal and distal colon sections for each animal from the CO, βI, GO, and βI+GO groups (27) . Apoptosis was evaluated as total number of apoptotic cells in normalappearing colonic crypt areas measured in 10 random microscopic fields consecutive (40X objective). This analysis was performed using an Image QWin Pro Plus Image Analysis System (Leica Imaging Systems Ltd., England) connected to a Leica DM2500 microscope. The image input was performed using a Leica DFC300FX digital CCD camera, and image processing, binarization and measurement were performed using a standard Leica QWin V3 program. Colonic crypt segmentation was performed by setting an automatic threshold level or interactively, by manual tracing, when necessary. The morphological criteria for the identification of apoptotic colonic cells (i.e., with cellular retraction and condensation, condensed or fragmented nuclear chromatin and formation of apoptotic bodies) in HE-stained sections were used as previously described (27) . Data are reported as mean number of apoptotic cells per crypt area analyzed (mm 2 ) per group.
PCNA and Bcl-2 Western blot analysis
Total and cytoplasmic protein extracts were prepared from the colonic mucosa samples of the animals using the T-PER and NE-PER reagents, respectively. Protein concentration was determined with the BCA protein assay kit. Samples of 150 µg total protein and of 450 µg cytoplasmic protein were used for PCNA and Bcl-2 expression analysis, respectively. The samples were separated by electrophoresis on 15% denaturing polyacrylamide gel (SDS-PAGE) in 1X Tris-glycine buffer. The proteins were then transferred from the gel to nitrocellulose membranes and blocked with the ECL-advanced kit blocking solution for PCNA analysis or with PBS containing 5% powdered milk for Bcl-2 analysis, for 1 h. After washing with PBS buffer containing 0.1% Tween-20, the membranes were incubated overnight at 4°C with the primary anti-PCNA antibody (1:10,000) diluted with the ECL-advanced kit blocking solution or with anti-Bcl-2 antibody (1:500) diluted in milk. The membranes were then incubated with the secondary antibody conjugated to horse radish peroxidase for 1 h at room temperature. The membranes were developed using the ECL-advanced and ECL kit for PCNA and Bcl-2 analysis, respectively. X-ray films were then exposed to the membranes. To quantify the band intensities, a densitometer (Imaging Densitometer, Model GS-700, Bio-Rad, USA) with specific software (Molecular Analyst, Bio-Rad) was used. To control for the amount of protein loaded, the nitrocellulose membrane was stained with Coomassie blue (8, 9, 30) .
Colonic βI and GO concentrations βI and GO quantification was performed by the method of Su et al. (31) with some modifications. Colonic mucosa samples from each group were powdered with liquid N 2 and homogenized in a Potter homogenizer with 400 µL absolute ethanol plus 10 ng methyl-β-ionone and 10 ng thimol (internal standard) for the quantification of βI and GO, respectively. Homogenates were centrifuged for 15 min at 10,000 g (4°C), the supernatants were collected and transferred to clean injection vials and 2 µL was injected into a gas chromatography/ mass spectrometry (GC-MS) system. Standard βI and GO solutions plus the same amount of internal standard added to the samples were used for the calibration curves that were calculated using the analyte/internal standard peak-area ratios versus the nominal concentrations of each standard. The samples and standards were injected into an HP6890 gas chromatographer (Agilent, USA) equipped with a CP Wax 58 -FFAP (Varian 25 m x 0.32 m x 0.2 µm) column. Injection was done in the splitless mode and the injection port was maintained at 200°C. The carrier gas used was helium, at a flow rate of 1.0 mL/min. The oven temperature was maintained at 50°C for 3 min and raised to 250°C at 20°C/min. The column effluent was monitored by a mass selective detector HP5973 (Agilent) using electron impact ionization with an ion source at 70 V and 200°C.
Statistical analysis
Data are reported as means ± SEM and all analyses were conducted using the STATISTICA 8.0 software (Statsoft, USA). Differences were considered to be statistically significant when P < 0.05.
Results
Weight gain and diet consumption
No differences were observed between the CO (control), βI, GO and βI+GO, groups regarding final body weight and average diet consumption during the 9 weeks of the experiment (data not shown). This suggests that isoprenoids had no toxicity at the doses administered. It is important to emphasize that the doses used (16 mg/100 g body weight βI and 25 mg/100 g body weight GO) were much lower than the respective LD 50 (LD 50 of βI = 329 mg/100 g; LD 50 of GO = 360 mg/100 g) (4, 5) .
Quantification of ACF in the proximal and distal colon
The βI, GO and βI+GO groups did not differ from the CO group in terms of the total number of ACF or ACF <4 or ACF ≥4 crypts in the proximal colon. Figure 3 presents the total number of ACF and the number of ACF <4 or ACF ≥4 crypts present in the distal colon of animals from the CO, βI, GO, and βI+GO groups. Compared to the CO group, the GO group showed a decreased (P ≤ 0.05) total number of ACF and ACF ≥4 crypts. However, there was no difference in the number of ACF <4 crypts in the distal colon compared to the CO group. Furthermore, no differences were observed between the CO, βI and βI+GO groups regarding the total number of ACF, ACF <4 or ACF ≥4 crypts in the distal colon. Figure 4 presents the total plasma cholesterol concentration of the N, CO, βI, GO, and βI+GO groups. Compared to the N group, the CO group exhibited an increased (P < 0.05) plasma cholesterol concentration. Compared with the CO group, the βI group exhibited a decreased (P ≤ 0.05) plasma cholesterol concentration, while no differences (P > 0.05) were observed in the GO and βI+GO groups.
Total plasma cholesterol concentration
Evaluation of DNA damage in the colonic mucosa Figure 5 shows the lengths of the comet of the colonic mucosa of rats from the N group, treated or not with HP, as well as of the colonic mucosa of rats from the CO, βI, GO, or βI+GO groups. Normal rat colonic mucosa samples treated with HP (HP group) showed comets of increased (P ≤ 0.05) lengths compared to those observed in the untreated ones (N group). When compared to the N group, the CO group had comets with increased (P ≤ 0.05) lengths. When compared to the CO group, the βI, GO, and βI+GO groups had comets with reduced (P ≤ 0.05) lengths, suggesting a reduction of DNA damage by isoprenoids.
Apoptosis in the colonic mucosa
Colonic apoptotic cells were easily detected in HEstained sections ( Figure 6A ). The apoptosis values in the proximal and distal colon from the CO, βI, GO, and βI+GO groups are shown in Figure 6B and C. Oral treatment with βI, GO or βI+GO did not alter the apoptosis levels in the proximal colon when compared to the CO group (P > 0.05). However, a significant increase in apoptosis levels was detected in the distal colon from the GO group when compared to the CO group (P < 0.05).
Expression of PCNA and Bcl-2 in the colonic mucosa
Compared to the N group, the CO group showed a 3.1-fold increase in PCNA protein expression. No differences (P > 0.05) were observed between the CO, βI, GO, and βI+GO groups regarding PCNA protein expression. Figure 7 shows Bcl-2 expression analysis using cytoplasmic protein extracts from the colonic mucosa of rats from the N, CO, βI, GO, or βI+GO groups. Compared to the N group, the CO group showed a 2.2-fold increase in Bcl-2 protein expression. Compared to the CO group, the GO group showed a 0.7-fold decrease (P ≤ 0.05) in Bcl-2 protein expression while no differences (P > 0.05) were observed in the βI and βI+GO groups.
Concentration of βI and GO in the colonic mucosa βI was not detected in the N, CO or GO groups. Compared to the CO group, the βI and βI+GO groups had higher (P ≤ 0.05) colonic mucosa concentrations of βI. Compared to the βI group, the βI+GO group had a lower (P ≤ 0.05) colonic mucosa concentration of βI. There was no difference (P > 0.05) in the colonic mucosa concentration of GO between the N and CO groups. Compared to the CO group, the GO group had a higher (P ≤ 0.05) colonic mucosa concentration of GO, while no differences were observed in the βI and βI+GO groups. Compared to the GO group, the βI+GO group showed a lower (P ≤ 0.05) colonic mucosa concentration of GO.
Discussion
The distal portion of the colon is the region where the incidence of neoplasms is most frequent in both rats and humans (32, 33) . The new data presented here showing that treatment with GO reduced the total number of ACF in this region, as well as the number of ACF ≥4 crypts, lesions with a more advanced and aggressive phenotype (33) , reinforce the idea that acyclic isoprenoids may be a chemopreventive agent against colon carcinogenesis. To the best of our knowledge, in vivo studies of chemoprevention with GO have only been conducted in liver, breast and pancreas carcinogenesis models, with inhibition of hepatic PNLs (9,10) and mammary (11, 34) and pancreatic (12) neoplastic lesions, respectively. Recently, βI was reported to have chemopreventive activity in liver (8, 10) , breast (3, 11) and colon (14) carcinogenesis. However, inhibition of total ACF and of ACF <4 or ACF ≥4 crypts by βI was not observed in the present study. Differences in the experimental design, such as the type of carcinogen, dose and mode of administration of βI and the strain of animals employed, could explain the differences in the results obtained by Janakiram et al. (14) and by us. Unexpectedly, the combination of βI and GO did not provide chemopreventive effects.
On the basis of in vitro studies conducted with combinations of isoprenoids, it has been proposed that the less potent compound could attenuate the tumor-suppressive action of the more potent one (25) . We investigated whether this absence of chemoprevention was due to alterations in the distribution of isoprenoids. We determined the concentrations of βI and GO in the colonic mucosa. Treatment with each compound individuals increased their respective concentration in the colonic mucosa. Animals treated with a mixture of the isoprenoids showed that the βI plus GO had lower concentrations compared to animals that were given βI and GO individually. It is possible that the reduced concentration of GO in the colonic mucosa was not sufficient to attain protective effects, suggesting that, when considering the combination of isoprenoids as a chemopreventive strategy, bioavailability issues should be considered.
Loss of the regulatory mechanism of HMG-CoA reductase and increase in cholesterol synthesis have been reported to occur during carcinogenesis (6) . This could explain the higher cholesterol concentration in the CO group, as compared to the N group. Treatment of birds, rats and mice with isoprenoids such as geranylgeraniol, limonene or βI resulted in the reduction of HMG-CoA reductase activity that was accompanied by a decrease in plasma cholesterol (8, 35, 36) . A decrease in the plasma total cholesterol was observed by us in the βI group. Although this cyclic isoprenoid did not have chemopreventive activity, its hypocholesterolemic effect should be highlighted. The chemopreventive activities of GO were not accompanied by a decrease in plasma cholesterol concentrations. Similar results were observed by others after treatment with farnesol, lanosterol and squalene of animals with colon carcinogenesis, and with GO in pancreas carcinogenesis (12, 16, 18) . As previously reported (9, 19, 37) , the chemopreventive effect of GO may not involve the inhibition of HMG-CoA reductase activity. Figure 7 . A, Bcl-2 Western blot analysis performed with cytoplasmic proteins extracted from the colonic mucosa of N rats and of animals treated with CO, βI, GO, or βI+GO during the initiation and post-initiation phases of colon carcinogenesis. Representative sample from 1 animal of the N group and from 2 animals from all other groups; a total of 3 (N group) and 6 (all other groups) animals were analyzed. B, Coomassie blue staining of the membrane as loading control. C, Quantification of membrane Bcl-2 levels in colon mucosa samples of N rats and animals treated with CO, βI, GO, or βI+GO during the initiation and post-initiation phases of colon carcinogenesis. The results are reported in relation to N animal colon mucosa, whose Bcl-2 protein level was considered as 1. Data are reported as means ± SEM. N = normal; CO = corn oil; βI = β-ionone; GO = geraniol; βI+GO = combination of βI and GO. a P ≤ 0.05 compared to the CO group (Student t-test for unpaired data). Dietary isoprenoids such as βI and GO have been shown to have antioxidant properties (14, 24, 38) . Treatment with these isoprenoids, individually or in combination, reduced DNA damage although only GO exhibited anticarcinogenic effects. It is important to mention that the Comet assay was performed under alkaline conditions that enable the detection of single-and double-stranded breaks, incomplete repair sites and alkali-labile sites, extending the amount of damage that can be detected when compared to neutral conditions (39) . These results suggest that antioxidant effects are not involved in the chemopreventive activity of GO during colon carcinogenesis. Since the induction of apoptosis could be associated with the anticarcinogenic effects of GO (9,10), colonic apoptotic cells were quantified in the present study using established morphological criteria (27) . Although GO inhibited DNA damage, the isoprenoid induced apoptosis specifically in the distal colon, suggesting that cell death induction could represent an important feature of the protective effects of GO.
Increase in the anti-apoptotic Bcl-2 protein occurs in the initial phases of colon carcinogenesis (23) , as also observed in the present study. Only the GO group exhibited lower levels of Bcl-2, suggesting that the inhibition of this protein could have a relevant role in apoptosis induction by this isoprenoid. The induction of apoptosis via the Bcl-2 family of proteins has been identified as one of the main mechanisms of action of isoprenoids, as observed for perillyl alcohol, geranylgeraniol and farnesol (21, 22) . It is important to highlight the lack of in vivo studies addressing the capacity of apoptosis modulation by GO, as induced in hepatic PNL (9, 10) . Moreover, since apoptosis is a cellular event that involves activation and/or suppression of various gene families (23) , it would be important to determine the influence of GO on other members of the Bcl-2 family, including pro-apoptotic ones such as Bax (22) .
In the present study, an increase in PCNA protein was observed in rats subjected to colon carcinogenesis, which could indicate an increase in cell proliferation (40) . On the other hand, none of the treatments with isoprenoids reduced the expression of this protein, suggesting that cell proliferation inhibition is not part of the chemopreventive activity of GO.
The present study advances our knowledge regarding the potential of dietary isoprenoids for the chemoprevention of colon carcinogenesis. GO represents a promising agent with inhibitory actions on colonic PNLs that are described here for the first time. Surprisingly, βI had little or no activity. Although the combination of cyclic and acyclic isoprenoids has been suggested as a synergistic chemopreventive strategy, issues such as bioavailability should be considered.
